Tisagenlecleucel Shows Comparable Efficacy, Superior Safety to Axicabtagene Ciloleucel Among Patients With R/R FL
According to a recent study, among chimeric antigen receptor T-cell (CAR T-cell) therapies, tisagenlecleucel was associated with superior safety outcomes when compared to axicabtagene ciloleucel among patients with relapsed/refractory (R/R) follicular lymphoma (FL).
Michael Dickinson, MBBS, Peter MacCallum Cancer Centre, Royal Melbourne Hospital and the University of Melbourne, Melbourne, Australia, and fellow study investigators used individual patient data from the ELARA trial, which used tisagenlecleucel, and aggregated published patient data from the ZUMA-5 trial, which used axicabtagene ciloleucel, to compare efficacy and safety outcomes in R/R FL using matching-adjusted indirect comparison methods.
After adjustments were made for baseline differences in the trial populations, study results determined that tisagenlecleucel (n= 52) compared with axicabtagene ciloleucel (n= 86) exhibited similar effects on overall response rate (ORR) (91.2% vs. 94.2%; P = .58), complete response rate (CRR) (74% vs. 79.1%; P = .60), progression-free survival (PFS) (hazard ratio [HR] [95% confidence interval (CI)]: 0.8 [0.4 to 1.9]; P = .67), and overall survival (OS) (HR [95% CI]: 0.5 [0.2 to 1.5]; P = .21).
Overall, study investigators determined that tisagenlecleucel demonstrated similar efficacy, but improved safety outcomes over axicabtagene ciloleucel, as seen by lower rates of any grade and grade ≥3 cytokine release syndrome and neurological events.
Source:
Dickinson M, Martinez-Lopez J, Jousseaume E, et al. Comparative efficacy and safety of tisagenlecleucel and axicabtagene ciloleucel among adults with r/r follicular lymphoma. Leukemia & Lymphoma. Published online January 5, 2024. doi: 10.1080/10428194.2023.2289854
